Nα-methylhistamine safety and efficacy in migraine prophylaxis: Phase I and Phase II studies

Headache

Volumn 43, Issue 4, 2003, Pages 389-394

  Millán Guerrero, Rebeca O ^a,d   Pineda Lucatero, Alicia G ^b   Hernández Benjamín, Trujillo ^a   Tene, Carlos E ^a   Pacheco, Mauro F ^c  

^a Hospital General de Zona IMSS   (Mexico)

^b Unidad de Investigación Epidemiológica Y en Servicios de Salud   (Mexico)

^c UNIVERSIDAD DE COLIMA   (Mexico)

^d NONE   (Mexico)

Author keywords

H3 receptors; Migraine prophylaxis; N methylhistamine; Pathophysiology; Safety and efficacy

Indexed keywords

HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; N METHYLHISTAMINE; ALPHA METHYLHISTAMINE; ALPHA-METHYLHISTAMINE; HISTAMINE AGONIST; HISTAMINE DERIVATIVE; HISTAMINE RECEPTOR;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; HEADACHE; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; ADOLESCENT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FEMALE; MALE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HISTAMINE AGONISTS; HUMANS; MALE; METHYLHISTAMINES; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, HISTAMINE; TREATMENT OUTCOME;

EID: 0037388547     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2003.03074.x     Document Type: Article

References (20)

1. Bartleson JD. Treatment of migraine headaches. Mayo Clin Proc. 1999;74:702-708.
2. Lance JW. Treatment of migraine. Lancet. 1992;339:1207-1209.
3. Peroutka SJ. The pharmacology of current antimigraine drugs. Headache. 1990;30(suppl 1):5-11.
4. Thomsen LL, Olesen JB. Nitric oxide in primary headache. Curr Opin Neurol. 2004;14:315-321.
5. Millán GR, Isais CM, Antonio OA, Pacheco CM. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache. 1999;39:576-580.
6. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983;302: 832-837.
7. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16:157-168.
8. Marcus DA. Migraine and tension-type headache. The questionable validity of current classification system. Clin J Pain. 1992;8:28-36.
9. Dimitriadou V, Rouleau A, Dam Trung Tuong M, et al. Functional relationship between mast cells and C-sensitive nerve fibres evidenced by histamine H3-receptor modulation in rat lung and spleen. Clin Sci. 1994;87:151-163.
10. Arrang JM, Garbarg M, Schwartz JC. Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. Neuroscience. 1987;23:149-157.
11. Ishikawa S, Speralakis N. A novel class H3 of histamine receptors on perivascular nerve terminals. Nature. 1987;327:158-160.
12. West RE Jr, Zweig A, Shih NY, Siegel MI, Egan RW, Clark MA. Identification of two H3 histamine receptor subtypes. Mol Pharmacol. 1990;38:610-613.
13. Göthert M, Garbarg M, Hey JA, Schlicker E, Schwartz JC, Levi R. New aspects of the role of histamine in cardiovascular function: identification, characterization, and potential pathophysiological importance of H3 receptors. Can J Pharmacol. 1995; 73:558-564.
14. Naranjo CA, Busto UE. Development of new drugs and regulation of new drugs. In: Naranjo CA, Souich PD, Bustos UE, eds. Methods in Clinical Pharmacy. Toronto: World Health Organization. Regional Program of Essential Drugs; 1992:6-15.
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
16. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia. 1991;11:1-12.
17. Hulley SB. Gove S, Cummings SR. Choosing the individuals who will participate in the study: specification and sample. In: Hulley SB, Cummings SR, eds. Design of Clinical Investigation. Spain: Harcourt Brace; 1997:21-55.
18. Babe KS, Serafín WE. Histamine, bradicinine and its antagonists. In: Goodman A, Gilman, eds. Pharmacological bases of therapeutics. México, DF: Interamerican McGraw-Hill; 1996:621-641.
19. Krabbe AA, Olesen J. Headache provocation by continuous intravenous infusion of histamine: clinical results and receptor mechanisms. Pain. 1980;134:253-259.
20. Lassen LH, Thomsen LL, Olesen J. Histamine induce migraine via the H1 receptor. Support for the NO hypothesis of migraine. Neuroreport. 1995;6: 1475-1479.